Physician profile
Luis E Velez
NPI 1053328336
$505,049.68
in general payments reported to CMS, 2019-2025
35 companies · $179K in 2025
The $179K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $22K · 2021: $46K · 2022: $53K · 2023: $81K · 2024: $103K · 2025: $179K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $157K · Consulting Fee: $87K · Travel and Lodging: $70K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $35K · Food and Beverage: $14K · Education: $76.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $156,688.70 |
| Consulting Fee | $86,591.50 |
| Travel and Lodging | $69,879.31 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $35,450.00 |
| Food and Beverage | $13,997.27 |
| Education | $76.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $331,296.87 | 2019-2025 | Jynarque, Voyxact, Tolvaptan |
| Travere Therapeutics, INC. | $159,640.96 | 2020-2025 | Filspari |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $8,291.58 | 2024-2025 | Tolvaptan |
| Amgen INC. | $645.75 | 2019-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $639.30 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $509.93 | 2022-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $486.59 | 2020-2025 | Acthar, Terlivaz |
| Horizon Therapeutics Plc | $384.89 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $343.63 | 2020-2024 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $317.66 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $270.48 | 2019-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $249.75 | 2022-2024 | |
| Vifor Pharma, INC. | $224.41 | 2019-2024 | Veltassa, Korsuva |
| Mallinckrodt Enterprises LLC | $216.15 | 2019 | |
| Alexion Pharmaceuticals, INC. | $211.36 | 2019-2024 | Soliris, Ultomiris |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $163.97 | 2022-2024 | |
| Corcept Therapeutics | $131.83 | 2025 | Korlym |
| Bard Peripheral Vascular, INC. | $127.94 | 2020 | |
| Novartis Pharmaceuticals Corporation | $120.99 | 2025 | |
| Cormedix INC. | $114.64 | 2024 | Defencath |
| Ardelyx, INC. | $94.21 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $81.86 | 2019-2022 | |
| Glaxosmithkline, LLC. | $73.99 | 2022-2025 | Benlysta, Shingrix, Arexvy |
| Nxstage Medical, INC. | $69.45 | 2019 | |
| Lilly USA, LLC | $68.47 | 2023-2025 | Jardiance, Mounjaro |
| Ani Pharmaceuticals, INC. | $61.75 | 2022-2025 | Purified Cortrophin Gel |
| Edwards Lifesciences Corporation | $46.35 | 2021 | |
| Janssen Pharmaceuticals, INC | $35.15 | 2021 | |
| La Jolla Pharmaceutical Company | $22.28 | 2019 | |
| Daiichi Sankyo INC. | $22.18 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.96 | 2022 | |
| Apellis Pharmaceuticals, INC. | $18.77 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.87 | 2025 | Xifaxan |
| Abbvie INC. | $16.17 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.